Correction: Tracking daratumumab clearance using mass spectrometry: implications on M protein monitoring and reusing daratumumab.

Autor: Abdallah N; Division of Hematology, Mayo Clinic, Rochester, MN, USA., Murray D; Department of Laboratory, Medicine and Pathology, Rochester, MN, USA., Dispenzieri A; Division of Hematology, Mayo Clinic, Rochester, MN, USA., Kapoor P; Division of Hematology, Mayo Clinic, Rochester, MN, USA., Gertz MA; Division of Hematology, Mayo Clinic, Rochester, MN, USA., Lacy MQ; Division of Hematology, Mayo Clinic, Rochester, MN, USA., Hayman SR; Division of Hematology, Mayo Clinic, Rochester, MN, USA., Buadi FK; Division of Hematology, Mayo Clinic, Rochester, MN, USA., Gonsalves W; Division of Hematology, Mayo Clinic, Rochester, MN, USA., Muchtar E; Division of Hematology, Mayo Clinic, Rochester, MN, USA., Leung N; Division of Hematology, Mayo Clinic, Rochester, MN, USA.; Division of Nephrology, Mayo Clinic, Rochester, MN, USA., Dingli D; Division of Hematology, Mayo Clinic, Rochester, MN, USA., Kourelis T; Division of Hematology, Mayo Clinic, Rochester, MN, USA., Warsame R; Division of Hematology, Mayo Clinic, Rochester, MN, USA., Binder M; Division of Hematology, Mayo Clinic, Rochester, MN, USA., Kyle RA; Division of Hematology, Mayo Clinic, Rochester, MN, USA., Rajkumar SV; Division of Hematology, Mayo Clinic, Rochester, MN, USA., Kumar S; Division of Hematology, Mayo Clinic, Rochester, MN, USA. kumar.shaji@mayo.edu.
Jazyk: angličtina
Zdroj: Leukemia [Leukemia] 2024 Aug; Vol. 38 (8), pp. 1864.
DOI: 10.1038/s41375-024-02308-5
Databáze: MEDLINE